SCRIPPS RESEARCH
INSTITUTIONAL BIOSAFETY COMMITTEE
MEETING MINUTES
September 10, 2025

I. MEETING

The Institutional Biosafety Committee (IBC) of Scripps Research held a meeting via videoconference September 10, 2025, commencing at 2 p.m. Pacific Time. The meeting was held pursuant to notice duly given and a quorum was present.

Committee Members Present		Committee Members Absent	Others Present
Juan Carlos de la Torre	Michael Bobardt	Jim Gohres	Amy Green
Elizabeth Ford	Smita Chopade	Stephen Munday	
Roberto Aiolfi	Elizabeth Montano	Raphael Park	
Mychelle Fernandez	Steven Robert Head	Cheryl Andreoli	
Elyse Walk	Case McNamara		

I. REVIEW OF PREVIOUS MEETING MINUTES

The Committee voted unanimously to approve the minutes of the August 13, 2025 IBC Meeting.

II. ANNOUNCEMENTS

None.

III. BIOSAFETY OFFICER & IBC ADMINISTRATOR'S REPORT

1. OLAW/The Guide requirements for Herpes B Virus training (from Calibr IACUC)
2. Update to Macaque sample exposure Grab and Go
3. IBC Policies and Procedures Update

IV. CONFLICT OF INTEREST

Case McNamara will abstain from voting on his protocol #09-14-16-04. Michael Bobardt will abstain from voting on the Gallay Lab protocol #02-12-20-03.

V. REVIEW OF PROTOCOLS

FULL COMMITTEE REVIEW

NEW

1. IBC Protocol #:	**09-10-25-01, Chen, Jason**
Title of Study:	Normal Blood Donor Services
Department:	Core Facilities
Primary Reviewer:	Mychelle Fernandez
Secondary Reviewer:	Steve Head
NIH Guidelines:	N/A
Biosafety Level:	BSL-2
Animal work:	☐ Yes ☒ No
Biosafety Inspection:	Inspection of CHWL 165-166 completed on 11/6/24.
Training:	Pending training.

Summary of Discussion: A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

Review outcome: Approved.

2. IBC Protocol #:	**09-10-25-02, Hangartner, Lars**
Title of Study:	Isolation and purification of IgA proteases for the analysis of IgA responses
Department:	Immunology & Microbiology
Primary Reviewer:	Roberto Aiolfi
Secondary Reviewer:	Michael Bobardt
NIH Guidelines:	III-A-1-a
Biosafety Level:	BSL-2+
Animal work:	☐Yes ☒No
Biosafety Inspection:	Inspection of IMM 309A, 310 completed on 2/5/24.
Training:	Training verified and on record.

Summary of Discussion: A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

The following action items were identified as needing to be updated on the protocol:

Study Design/Project Description
A description of the genes that will be introduced into bacteria is needed here. A list of the agents that will be genetically modified is also needed.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

MIGRATIONS

1. IBC Protocol #:	**09-14-16-04, McNamara, Case**
Title of Study:	Drug Discovery for Tuberculosis
Department:	Biology- Calibr
Primary Reviewer:	Michael Bobardt
Secondary Reviewer:	Roberto Aiolfi
NIH Guidelines:	III-D-1
Biosafety Level:	BSL-2
Animal work:	☐Yes ☒No
Biosafety Inspection:	Inspection of Calibr 124E completed on 9/5/23.
Training:	Training verified and on record.

Summary of Discussion: A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

The following action items were identified as needing to be updated on the protocol:

Location of Study
The location of the BSL-3 work needs to be updated to the renovated facility.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

2. IBC Protocol #:	**02-12-20-03, Gallay, Philippe**
Title of Study:	Hepatic disease studies
Department:	Immunology & Microbiology
Primary Reviewer:	Cheryl Andreoli
Secondary Reviewer:	Beth Ford
NIH Guidelines:	III-D-3, III-D-4-b
Biosafety Level:	BSL-2, ABSL-2
Animal work:	☒Yes ☐No
Biosafety Inspection:	Inspection of IMM 214 completed on 5/13/25.
Training:	Training verified and on record.

Summary of Discussion: A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

The following action items were identified as needing to be updated on the protocol:

Location of Study
The location of the BSL2+ space needs to be added.

Infectious Agents
The source of the agents needs to be added.

Vertebrate or Invertebrate Animals
Confirmation of the external source of animals is needed.
Clarification on the use of anesthetics during tail vein injections is needed.
Blood collection and restraint measures need to be added.

Study Design/Project Description
Door cards need to be updated.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

BIOSAFETY REVIEW

1. IBC Protocol #:	**03-09-22-03, Ward, Andrew**
Title of Study:	Structural Characterization of pathogenic proteins and the immune response
Department:	ISCB
NIH Guidelines:	III-D-1, III-D-2, III-D-7
Biosafety Level:	BSL-2
Animal work:	☐Yes ☒No
Training:	Pending Training.
REVIEW OUTCOME:	**Pending approval.**

VI. ADJOURNMENT

The next scheduled IBC meeting is **Wednesday, October 8, 2025,** via Teams at 2:00 PM. If full committee review protocols are not received by the next deadline date and there are no agenda items for full committee discussion, the meeting will be canceled. Members will be notified via e-mail of meeting cancellations one week before the scheduled meeting.